Levothyroxine

證據等級: L5

預測適應症: 10 個

Levothyroxine: From Thyroid Hormone Replacement (Hypothyroidism) to Endemic Goiter

One-Sentence Summary

Levothyroxine is a synthetic thyroid hormone (T4), long established as replacement therapy for hypothyroidism. The TxGNN model predicts it may be effective for Endemic Goiter, but the supporting evidence base is thin — 1 clinical trial (not testing levothyroxine directly) and 20 publications, mostly reviews and older observational studies, currently support this direction. Note: the evidence pack contains no original-indication or SAHPRA-license text for this drug — the indication above reflects levothyroxine’s globally established pharmacological use, not a value extracted from the pack.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (established use: thyroid hormone replacement / hypothyroidism)
Predicted New Indication	Endemic Goiter
TxGNN Prediction Score	99.81%
Evidence Level	L4 (mechanistic rationale only; no dedicated RCT of levothyroxine in this indication)
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold (Research Question stage)

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for this drug is not available in the evidence pack. Based on known pharmacology, levothyroxine (synthetic T4) suppresses thyroid-stimulating hormone (TSH) secretion via the hypothalamic-pituitary-thyroid axis, and its efficacy as thyroid hormone replacement in hypothyroidism is well established.

Endemic goiter is caused primarily by iodine deficiency, and first-line treatment is iodine supplementation rather than thyroid hormone replacement. Levothyroxine’s role here is mechanistically indirect: by suppressing TSH, it can reduce goiter volume as an adjunctive/suppressive measure, but it does not address the underlying iodine deficiency. This is consistent with the evidence-pack’s own assessment: “Endemic goiter is primarily caused by iodine deficiency; iodine supplementation is the first-line treatment. Levothyroxine serves only as an adjunctive suppressive therapy, and the mechanistic link is indirect.”

Notably, other predicted indications for levothyroxine in this same evidence pack — particularly nodular goiter (rank 3, evidence level L1, 7 clinical trials including a 1,024-patient Phase 4 RCT) and nontoxic goiter (rank 5, evidence level L2, including a head-to-head RCT vs. radioiodine) — represent much stronger and more direct extensions of levothyroxine’s known TSH-suppressive mechanism, and may warrant separate evaluation alongside this report’s primary candidate.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04482907	N/A	Completed	68	Randomized placebo-controlled study of Anethum graveolens L. (Dill) extract — not levothyroxine — in thyroiditis and nodular goiter patients; evaluated hormone levels and nodule size by ultrasound over 90 days. Relevance graded C (tests a different agent; disease-area overlap only, not a direct test of levothyroxine in endemic goiter).

No clinical trial in this evidence pack directly tests levothyroxine in endemic goiter.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3278876	1988	Multicenter comparative study	Deutsche medizinische Wochenschrift	74 patients with diffuse endemic goiter treated 6 months with levothyroxine alone (150mcg/day, n=35) vs. levothyroxine+iodide (100mcg+130.8mcg KI/day, n=39), followed by 3-month iodide prophylaxis; goiter volume reduction assessed at 3, 6, 9 months. Most directly relevant record in the pack.
2031356	1991	Review	World Journal of Surgery	Establishes iodine deficiency as the primary cause of endemic goiter; iodine supplementation as the core preventive/therapeutic strategy.
36839362	2023	Review	Nutrients	Overview of iodine deficiency and iodine prophylaxis, including thyroid hormone synthesis requirements.
7704809	1994	Review	Current Therapy in Endocrinology and Metabolism	General review of endemic goiter etiology and management.
4312017	1969	Cohort	American Journal of Clinical Nutrition	Prophylaxis/treatment of endemic goiter with iodized oil in rural Ecuador and Peru.
25629792	2015	Cohort	Current Medical Research and Opinion	Effect of maternal iodine supplementation on thyroid function and birth outcomes in goiter-endemic areas (n=460).
6309889	1983	Not classified	J Clin Endocrinol Metab	Iodized oil injection in 58 goitrous patients from an iodine-deficient area in Greece; goiter size decreased with hormonal changes tracked over 6 months.
3090091	1986	Not classified	J Clin Endocrinol Metab	Goiter prevalence (65%) and thyroid function survey in an endemic iodine-deficient region of northern Italy (n=1218).
2997259	1985	Not classified	J Clin Endocrinol Metab	Longitudinal study of oral vs. IM iodized oil in Sudanese schoolchildren; goiter prevalence reduced from 67% to 36% (oral) and 71% to 42% (IM) at 1 year.
6304776	1983	Not classified	Progress in Clinical and Biological Research	TSH secretion and regulation in endemic goiter and endemic cretinism; inverse relationship between iodine intake and serum TSH.

None of the retrieved literature is a randomized controlled trial testing levothyroxine specifically against endemic goiter; the strongest record (PMID 3278876) is a small multicenter comparative study, consistent with the assigned L4 evidence level.

South Africa Market Information

Levothyroxine is not currently registered/marketed in South Africa according to this evidence pack (SAHPRA registrations: 0). No license records were available to extract product names, dosage forms, or approved indication text.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: the evidence pack flags TFDA/SAHPRA label warnings and contraindications as a Blocking data gap (DG001) — this must be resolved before a full S1 safety screening can be completed.

Conclusion and Next Steps

Decision: Hold (Research Question stage)

Rationale: The mechanistic link between levothyroxine and endemic goiter is indirect (TSH suppression as an adjunct, not the causal iodine-deficiency treatment), and no clinical trial or high-tier literature directly supports this specific drug-indication pair. Evidence level L4 is insufficient to progress beyond a research question.

To proceed, the following is needed:

SAHPRA-approved PI warnings, contraindications, and drug interaction data (currently a Blocking gap, DG001)
Verified mechanism of action data for levothyroxine (DG002)
A dedicated comparative or randomized study of levothyroxine (with/without iodide) specifically in endemic goiter populations
Consider parallel evaluation of the pack’s higher-evidence candidates — nodular goiter (L1) and nontoxic goiter (L2) — where levothyroxine’s TSH-suppressive mechanism is directly and robustly supported
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.